An unfinished Specialty Chems sculpture

04/03/25 -"Arkema had announced strong ambitions to become a pure-play specialty chemicals company by 2024 at the 2020 CMD. It looked the company’s strong portfolio rotation efforts ran out of steam before ..."

Executive summary
Conflict of interest

Pages

Language

English

Published on

04/03/25

Download

You may also be interested by these reports :

03/06/25

Johnson Matthey

We view the divestment of Catalyst Technologies as a strategic misstep, although we acknowledge that Johnson Matthey’s (JM) current focus is on free ...

01/06/25

REC Silicon

Hanwha’s offer to acquire all REC Silicon shares presents an opportunity for investors to recoup some funds. The management has encountered ...

28/05/25

Chemicals

German electricity price debate – Who would still profit?

28/05/25

BRAIN Biotech AG

Structural weakness persists, breakeven prospects slip further away

EXECUTIVE SUMMARY

Updates

Pension Risks

Target & Opinion

Governance & Management

Business & Trends

Graphics : Momentum

Money Making

Graphics : MACD & Volumes

Debt

Graphics : Sensitivities

Valuation

Sector: Performance

DCF

Sector: Key data

NAV/SOTP

Sector: Ratios & Valorisation

Worth knowing

Sector: Peers

Financials

Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking

Trading in corporate shares

Analyst ownership

Advising of corporate (strategy, marketing, debt, etc)

Research paid for by corporate

Provision of corporate access paid for by corporate

Link between and a banking entity

Brokerage activity at AlphaValue